Tesofensine vs Tirzepatide

These sit in different classes. Tesofensine is a metabolic compound; Tirzepatide is a GLP-1 / incretin agonist. They get compared because of where they overlap, not because they are interchangeable.

The overlap is appetite control and fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — Tesofensine rates 5/5 for appetite control and Tirzepatide rates 5/5. Outside that overlap only Tirzepatide goes further, carrying weight for metabolic health; Tesofensine's declared goals stop at the overlap.

Tirzepatide sits one step firmer: an approved label and the randomized trial package behind it — head-to-head trials put its average weight loss above semaglutide. Tesofensine has approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

Tesofensine is taken by mouth; Tirzepatide is a subcutaneous injection. That is the difference most people actually feel: Tirzepatide means reconstituting a vial and injecting; Tesofensine does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

Half-lives are close — 9.2 days for Tesofensine, 5 days for Tirzepatide — yet the schedules are not: once daily versus once a week. Similar clearance and different dosing means the difference comes from protocol convention, not from how fast either one leaves you.

One of these has an end date and the other does not: Tesofensine runs 24 weeks, Tirzepatide runs no fixed cycle. An open-ended compound is a standing commitment, not a course you finish. Tirzepatide also escalates through a titration schedule rather than holding one dose, so its first weeks are not its steady state.

The contraindication lists are not the same: Tesofensine flags under 18, which Tirzepatide does not; Tirzepatide flags MTC or MEN2 history, pancreatitis history, and thyroid disease, which Tesofensine does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

Tirzepatide is rated intermediate here and Tesofensine advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.